Search Result

Results for "

DYRK1A/B

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (4) Bcl-2 Family (2) c-Myc (2) Caspase (2) CDK (6) DNA/RNA Synthesis (2) DYRK (22) GSK-3 (1) PARP (2)
By Research Areas:	Cancer (15) Metabolic Disease (2) Neurological Disease (7)

Inhibitors & Agonists

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-147060

Dyrk1A-IN-3	DYRK	Neurological Disease
Dyrk1A-IN-3 (Compound 8b), a highly selective dual-specificity tyrosine-regulated kinase 1A (DYRK1A) inhibitor, maintains high levels of DYRK1A binding affinity (IC₅₀=76 nM). Dyrk1A-IN-3 can be used for the research of neurodegenerative disorders such as Alzheimer’s Disease, Huntington’s Disease, and Parkinson’s Disease .

HY-146221

Dyrk1A-IN-5 1 Publications Verification	DYRK	Neurological Disease
Dyrk1A-IN-5 (Compound 5j) is a potent and selective *DYRK1A* inhibitor, with an IC₅₀ of 6 nM. yrk1A-IN-5 exhibits significant selectivity for DYRK1B (IC₅₀ = 600 nM) and CLK1 (IC₅₀ = 500 nM), but shows almost no inhibition of DYRK2 (IC₅₀ > 10 μM). Dyrk1A-IN-5 can be used for Down syndrome research .

HY-108476

INDY 2 Publications Verification	DYRK	Cancer
INDY is a potent and ATP-competitive *Dyrk1A* and *Dyrk1B* inhibitor with IC₅₀s of 0.24 μM and 0.23 μM, respectively. INDY binds in the ATP pocket of the enzyme and has a K_i value of 0.18 μM for Dyrk1A. INDY sharply reduces the self-renewal capacity of normal and tumorigenic cells in primary Glioblastoma (GBM) cell lines and neural progenitor cells .

HY-146337

Dyrk1A/B-IN-1	DYRK	Cancer
Dyrk1A/B-IN-1 (compound 3n) is a potent, selective and cell-permeable *DYRK1A* and *DYRK1B* inhibitor with K_is of 67.8 nM and 237.9 nM, and IC₅₀s of 1.1 μM and 0.8 μM, respectively. Dyrk1A/B-IN-1 is not toxic to human cells. Dyrk1A/B-IN-1 can be used for researching DYRK1A and DYRK1B cellular functions and their role in pathologies .

HY-159496

Dyrk1A-IN-10	DYRK	Metabolic Disease
Dyrk1A-IN-10 (compound B4) is a *DYRK1A* inhibitor with antidiabetic activity. Dyrk1A-IN-10 can promote pancreatic β-cell proliferation, increase insulin secretion, and lower blood sugar .

HY-108475

ProINDY	DYRK	Cancer
ProINDY, a prodrug of INDY (HY-108476), is a *DYRK1A* and *DYRK1B* inhibitor. ProINDY effectively recovers Xenopus embryos from head malformation induced by Dyrk1A overexpression .

HY-144695

Dyrk1A/α-synuclein-IN-1	DYRK	Neurological Disease
Dyrk1A/α-synuclein-IN-1 (Compound b1) is a dual *Dyrk1A* and α-synuclein aggregation inhibitor with IC₅₀ values of 177 nM and 10.5 µM, respectively. Dyrk1A/α-synuclein-IN-1 has high predictive CNS penetration and neuroprotective effect .

HY-144696

Dyrk1A/α-synuclein-IN-2	DYRK	Neurological Disease
Dyrk1A/α-synuclein-IN-2 (Compound b20) is a dual *Dyrk1A* and α-synuclein aggregation inhibitor with an IC₅₀ of 7.8 µM for α-synuclein. Dyrk1A/α-synuclein-IN-2 has high predictive CNS penetration and neuroprotective effect .

HY-144614

JH-XVII-10	DYRK Apoptosis	Neurological Disease Cancer
JH-XVII-10 is a potent, selective and orally active *DYRK1A* and *DYRK1B* inhibitor with IC₅₀s of 3 nM and 5 nM for *DYRK1A* and *DYRK1B*, respectively. JH-XVII-10 shows antitumor efficacy in neck squamous cell carcinoma (HNSCC) cell lines .

HY-144617

JH-XIV-68-3	DYRK	Cancer
JH-XIV-68-3 is a selective macrocyclic inhibitor of *DYRK1A/B. JH-XIV-68-3 displays selectivity for DYRK1A* and close family member DYRK1B in biochemical and cellular assays. JH-XIV-68-3 demonstrates antitumor efficacy in head and neck squamous cell carcinoma (HNSCC) cell lines .

HY-12838

RO5454948 1 Publications Verification Mirk-IN-1; DYRK1B/A-IN-1	DYRK	Cancer
RO5454948 (Compound 9) is the inhibitor for *Dyrk1B* and *Dyrk1A* with IC₅₀ of 68 nM and 22 nM. RO5454948 exhibits cytotoxicity in cancer cell SW620 with EC₅₀ of 1.9 μM .

HY-128759

DYRKs-IN-2	DYRK	Cancer
DYRKs-IN-2 (Example 132) is a potent *DYRKs* inhibitor with IC₅₀s of 30.6 nM and 12.8 nM for DYRK1B and DYRK1A, respectively. DYRKs-IN-2 has antitumor activity .

HY-111380

EHT 1610 2 Publications Verification	DYRK	Neurological Disease
EHT 1610 is a potent inhibitor of *DYRK, with IC₅₀s* of 0.36 nM (DYRK1A), 0.59 nM (DYRK1B), respectively. EHT 1610 exhibits antileukemia effect, regulates cell cycle and induces cell apoptosis ^- .

HY-128758

DYRKs-IN-1	DYRK	Cancer
DYRKs-IN-1 is a potent *DYRKs* (Dual-specificity tyrosine-phosphorylation-regulated kinases) inhibitor with IC₅₀s of 5 nM and 8 nM for DYRK1A and DYRK1B, respectively. DYRKs-IN-1 has antitumor activity .

HY-128758A

DYRKs-IN-1 hydrochloride	DYRK	Cancer
DYRKs-IN-1 hydrochloride is a potent *DYRKs* (Dual-specificity tyrosine-phosphorylation-regulated kinases) inhibitor with IC₅₀s of 5 nM and 8 nM for DYRK1A and DYRK1B, respectively. DYRKs-IN-1 hydrochloride has antitumor activity .

HY-15951

ML167 CID44968231; NCGC00188654	CDK DYRK	Cancer
ML167 is a highly selective Cdc2-like kinase 4 (Clk4) inhibitor with IC₅₀ of 136 nM, >10-fold selectivity for closely related kinases Clk1, Clk2, Clk3 and Dyrk1A/1B .

HY-77324S

4-(Trifluoromethyl)aniline-d4 4-Aminobenzotrifluoride-d₄	DYRK	Cancer
4-(Trifluoromethyl)aniline-d₄ (4-Aminobenzotrifluoride-d₄) is deuterium labeled 4-(Trifluoromethyl)aniline. 4-(Trifluoromethyl)aniline is a DYRK1A and DYRK1B kinase inhibitor with IC₅₀s of 54.84 nM and 186.40 nM, respectively .

HY-111379

EHT 5372	DYRK CDK GSK-3	Neurological Disease Metabolic Disease Cancer
EHT 5372 is a highly potent and selective inhibitor of *DYRK's* family kinases with IC₅₀s of 0.22, 0.28, 10.8, 93.2, 22.8, 88.8, 59.0, 7.44, and 221 nM for *DYRK1A, DYRK1B, DYRK2, DYRK*3, CLK1, CLK2, CLK4, GSK-3α, and GSK-3β, respectively .

HY-155723

Leucettinib-92	CDK DYRK	Others
Leucettinib-92 (compound 92) is an inhibitor of DYRK/CLK kinase, The IC₅₀s are 147 nM (CLK1), 39 nM (CLK2), 5.2 nM (CLK4), 0.8 μM (CLK3), 124 nM (DYRK1A), 204 nM (DYRK1B), 0.16 μM (DYRK2), respectively. 1.0 μM (DYRK3), 0.52 μM (DYRK4), 2.78 μM (GSK3) .

HY-X0009

Tambiciclib 1 Publications Verification GFH009; JSH-009; SLS009	CDK DYRK Apoptosis Bcl-2 Family c-Myc Caspase PARP DNA/RNA Synthesis	Cancer
Tambiciclib (GFH009, JSH-009) is an orally active, highly potent and selective CDK9 inhibitor (IC₅₀ = 1 nM), demonstrating >200-fold selectivity over other CDKs, >100-fold selectivity over *DYRK1A*/B, and excellent selectivity over 468 kinases/mutants. Tambiciclib demonstrates potent in vitro and in vivo antileukemic efficacy in acute myeloid leukemia (AML) mouse models by inhibiting RNA Pol II phosphorylation, downregulating MCL1 and MYC, and inducing apoptosis. Tambiciclib can be used for AML research .

HY-X0009A

Tambiciclib dimaleate GFH009 dimaleate; JSH-009 dimaleate; SLS009 dimaleate	CDK DYRK Apoptosis Bcl-2 Family c-Myc Caspase PARP DNA/RNA Synthesis	Cancer
Tambiciclib (GFH009, JSH-009) dimaleate is an orally active, highly potent and selective CDK9 inhibitor (IC₅₀ = 1 nM), demonstrating >200-fold selectivity over other CDKs, >100-fold selectivity over *DYRK1A*/B, and excellent selectivity over 468 kinases/mutants. Tambiciclib dimaleate demonstrates potent in vitro and in vivo antileukemic efficacy in acute myeloid leukemia (AML) mouse models by inhibiting RNA Pol II phosphorylation, downregulating MCL1 and MYC, and inducing apoptosis. Tambiciclib dimaleate can be used for AML research .

HY-112296

T025 3 Publications Verification	CDK Apoptosis DYRK	Cancer
T025 is an orally active and highly potent inhibitor of Cdc2-like kinase (CLKs), with K_d values of 4.8, 0.096, 6.5, 0.61, 0.074, 1.5 and 32 nM for CLK1, CLK2, CLK3, CLK4, DYRK1A, DYRK1B and DYRK2, respectively. T025 induces caspase-3/7-mediated cell apoptosis. T025 reduces CLK-dependent phosphorylation. T025 exerts anti-proliferative activities in both hematological and solid cancer cell lines (IC₅₀ values: 30-300 nM). T025 has an anti-tumor efficiency, mainly for MYC-driven disease research .

4-(Trifluoromethyl)aniline-d4
4-(Trifluoromethyl)aniline-d₄ (4-Aminobenzotrifluoride-d₄) is deuterium labeled 4-(Trifluoromethyl)aniline. 4-(Trifluoromethyl)aniline is a DYRK1A and DYRK1B kinase inhibitor with IC₅₀s of 54.84 nM and 186.40 nM, respectively .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.